{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T05:26:48Z","timestamp":1768886808961,"version":"3.49.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,5,28]],"date-time":"2015-05-28T00:00:00Z","timestamp":1432771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,5,28]],"date-time":"2015-05-28T00:00:00Z","timestamp":1432771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Genes Immun"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1038\/gene.2015.11","type":"journal-article","created":{"date-parts":[[2015,5,28]],"date-time":"2015-05-28T13:28:47Z","timestamp":1432819727000},"page":"321-329","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Hepatic expression levels of interferons and interferon-stimulated genes in patients with chronic hepatitis C: A phenotype\u2013genotype correlation study"],"prefix":"10.1038","volume":"16","author":[{"given":"M","family":"Noureddin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Rotman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Rehermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T J","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,5,28]]},"reference":[{"issue":"Suppl 1","key":"BFgene201511_CR1","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/j.1478-3231.2008.01927.x","volume":"29","author":"LB Seeff","year":"2009","unstructured":"Seeff LB . The history of the \"natural history\" of hepatitis C (1968-2009). Liver Int 2009; 29 (Suppl 1): 89\u201399.","journal-title":"Liver Int"},{"key":"BFgene201511_CR2","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1002\/hep.22759","volume":"49","author":"MG Ghany","year":"2009","unstructured":"Ghany MG, Strader DB, Thomas DL, Seeff LB . Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335\u20131374.","journal-title":"Hepatology"},{"key":"BFgene201511_CR3","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1056\/NEJMra1213651","volume":"368","author":"TJ Liang","year":"2013","unstructured":"Liang TJ, Ghany MG . Current and future therapies for hepatitis C virus infection. N Engl J Med 2013; 368: 1907\u20131917.","journal-title":"N Engl J Med"},{"key":"BFgene201511_CR4","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1056\/NEJMe1403619","volume":"370","author":"TJ Liang","year":"2014","unstructured":"Liang TJ, Ghany MG . Therapy of Hepatitis C - Back to the Future. N Engl J Med 2014; 370: 2043\u20132047.","journal-title":"N Engl J Med"},{"key":"BFgene201511_CR5","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1172\/JCI75938","volume":"124","author":"EG Meissner","year":"2014","unstructured":"Meissner EG, Wu D, Osinusi A, Bon D, Virtaneva K, Sturdevant D et al. Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. J Clin Invest 2014; 124: 3352\u20133363.","journal-title":"J Clin Invest"},{"key":"BFgene201511_CR6","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1093\/infdis\/jit827","volume":"209","author":"EG Meissner","year":"2014","unstructured":"Meissner EG, Bon D, Prokunina-Olsson L, Tang W, Masur H, O'Brien TR et al. IFNL4-DeltaG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin. J Infect Dis 2014; 209: 1700\u20131704.","journal-title":"J Infect Dis"},{"key":"BFgene201511_CR7","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1053\/j.gastro.2011.12.055","volume":"142","author":"E Thomas","year":"2012","unstructured":"Thomas E, Gonzalez VD, Li Q, Modi AA, Chen W, Noureddin M et al. HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology 2012; 142: 978\u2013988.","journal-title":"Gastroenterology"},{"key":"BFgene201511_CR8","doi-asserted-by":"publisher","first-page":"7034","DOI":"10.1073\/pnas.0707882105","volume":"105","author":"M Sarasin-Filipowicz","year":"2008","unstructured":"Sarasin-Filipowicz M, Oakeley EJ, Duong FH, Christen V, Terracciano L, Filipowicz W et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A. 2008; 105: 7034\u20137039.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"BFgene201511_CR9","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1053\/j.gastro.2005.01.059","volume":"128","author":"L Chen","year":"2005","unstructured":"Chen L, Borozan I, Feld J, Sun J, Tannis LL, Coltescu C et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 2005; 128: 1437\u20131444.","journal-title":"Gastroenterology"},{"key":"BFgene201511_CR10","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nature08309","volume":"461","author":"D Ge","year":"2009","unstructured":"Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399\u2013401.","journal-title":"Nature"},{"key":"BFgene201511_CR11","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/ng.449","volume":"41","author":"Y Tanaka","year":"2009","unstructured":"Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105\u20131109.","journal-title":"Nat Genet"},{"key":"BFgene201511_CR12","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1038\/ng.447","volume":"41","author":"V Suppiah","year":"2009","unstructured":"Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100\u20131104.","journal-title":"Nat Genet"},{"key":"BFgene201511_CR13","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/nature08463","volume":"461","author":"DL Thomas","year":"2009","unstructured":"Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798\u2013801.","journal-title":"Nature"},{"key":"BFgene201511_CR14","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1053\/j.gastro.2009.12.056","volume":"138","author":"A Rauch","year":"2010","unstructured":"Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138: 1338\u20131345 45 e1-7.","journal-title":"Gastroenterology"},{"key":"BFgene201511_CR15","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/ng.2521","volume":"45","author":"L Prokunina-Olsson","year":"2013","unstructured":"Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 2013; 45: 164\u2013171.","journal-title":"Nat Genet"},{"key":"BFgene201511_CR16","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1084\/jem.20130012","volume":"210","author":"S Bibert","year":"2013","unstructured":"Bibert S, Roger T, Calandra T, Bochud M, Cerny A, Semmo N et al. IL28B expression depends on a novel TT\/-G polymorphism which improves HCV clearance prediction. J Exp Med 2013; 210: 1109\u20131116.","journal-title":"J Exp Med"},{"key":"BFgene201511_CR17","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/ni.2758","volume":"15","author":"AP McFarland","year":"2014","unstructured":"McFarland AP, Horner SM, Jarret A, Joslyn RC, Bindewald E, Shapiro BA et al. The favorable IFNL3 genotype escapes mRNA decay mediated by AU-rich elements and hepatitis C virus-induced microRNAs. Nat Immunol 2014; 15: 72\u201379.","journal-title":"Nat Immunol"},{"key":"BFgene201511_CR18","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1053\/j.gastro.2010.10.004","volume":"139","author":"A Balagopal","year":"2010","unstructured":"Balagopal A, Thomas DL, Thio CL . IL28B and the control of hepatitis C virus infection. Gastroenterology 2010; 139: 1865\u20131876.","journal-title":"Gastroenterology"},{"key":"BFgene201511_CR19","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1002\/hep.25897","volume":"56","author":"H Park","year":"2012","unstructured":"Park H, Serti E, Eke O, Muchmore B, Prokunina-Olsson L, Capone S et al. IL-29 is the dominant type III interferon produced by hepatocytes during acute hepatitis C virus infection. Hepatology 2012; 56: 2060\u20132070.","journal-title":"Hepatology"},{"key":"BFgene201511_CR20","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1053\/j.gastro.2010.04.049","volume":"139","author":"M Honda","year":"2010","unstructured":"Honda M, Sakai A, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y et al. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010; 139: 499\u2013509.","journal-title":"Gastroenterology"},{"key":"BFgene201511_CR21","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1053\/j.gastro.2010.11.039","volume":"140","author":"MT Dill","year":"2011","unstructured":"Dill MT, Duong FH, Vogt JE, Bibert S, Bochud PY, Terracciano L et al. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 2011; 140: 1021\u20131031.","journal-title":"Gastroenterology"},{"key":"BFgene201511_CR22","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.jhep.2010.09.019","volume":"54","author":"H Abe","year":"2011","unstructured":"Abe H, Hayes CN, Ochi H, Maekawa T, Tsuge M, Miki D et al. IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy. J Hepatol 2011; 54: 1094\u20131101.","journal-title":"J Hepatol"},{"key":"BFgene201511_CR23","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1002\/jmv.22158","volume":"83","author":"H Abe","year":"2011","unstructured":"Abe H, Hayes CN, Ochi H, Tsuge M, Miki D, Hiraga N et al. Inverse association of IL28B genotype and liver mRNA expression of genes promoting or suppressing antiviral state. J Med Virol 2011; 83: 1597\u20131607.","journal-title":"J Med Virol"},{"key":"BFgene201511_CR24","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/hep.24623","volume":"55","author":"Y Asahina","year":"2012","unstructured":"Asahina Y, Tsuchiya K, Muraoka M, Tanaka K, Suzuki Y, Tamaki N et al. Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response. Hepatology 2012; 55: 20\u201329.","journal-title":"Hepatology"},{"key":"BFgene201511_CR25","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1002\/hep.23912","volume":"52","author":"TJ Urban","year":"2010","unstructured":"Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, Cronin KD et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 2010; 52: 1888\u20131896.","journal-title":"Hepatology"},{"key":"BFgene201511_CR26","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1002\/hep.26506","volume":"58","author":"M Noureddin","year":"2013","unstructured":"Noureddin M, Wright EC, Alter HJ, Clark S, Thomas E, Chen R et al. Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. Hepatology 2013; 58: 1548\u20131557.","journal-title":"Hepatology"},{"key":"BFgene201511_CR27","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1136\/gutjnl-2012-303852","volume":"63","author":"Y Rotman","year":"2014","unstructured":"Rotman Y, Noureddin M, Feld JJ, Guedj J, Witthaus M, Han H et al. Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C. Gut 2014; 63: 161\u2013169.","journal-title":"Gut"},{"key":"BFgene201511_CR28","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1038\/ng.447","volume":"41","author":"V Suppiah","year":"2009","unstructured":"Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100\u20131104.","journal-title":"Nat Genet"},{"key":"BFgene201511_CR29","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1002\/jmv.21310","volume":"80","author":"V Meier","year":"2008","unstructured":"Meier V, Mihm S, Ramadori G . Interferon-alpha therapy does not modulate hepatic expression of classical type I interferon inducible genes. J Med Virol 2008; 80: 1912\u20131918.","journal-title":"J Med Virol"},{"key":"BFgene201511_CR30","doi-asserted-by":"publisher","first-page":"4841","DOI":"10.1128\/MCB.00224-09","volume":"29","author":"M Sarasin-Filipowicz","year":"2009","unstructured":"Sarasin-Filipowicz M, Wang X, Yan M, Duong FH, Poli V, Hilton DJ et al. Alpha interferon induces long-lasting refractoriness of JAK-STAT signaling in the mouse liver through induction of USP18\/UBP43. Mol Cell Biol 2009; 29: 4841\u20134851.","journal-title":"Mol Cell Biol"},{"key":"BFgene201511_CR31","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1002\/hep.21167","volume":"43","author":"RE Lanford","year":"2006","unstructured":"Lanford RE, Guerra B, Lee H, Chavez D, Brasky KM, Bigger CB . Genomic response to interferon-alpha in chimpanzees: implications of rapid downregulation for hepatitis C kinetics. Hepatology 2006; 43: 961\u2013972.","journal-title":"Hepatology"},{"key":"BFgene201511_CR32","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1046\/j.1365-2893.2003.00477.x","volume":"11","author":"D Fujiwara","year":"2004","unstructured":"Fujiwara D, Hino K, Yamaguchi Y, Kubo Y, Yamashita S, Uchida K et al. Type I interferon receptor and response to interferon therapy in chronic hepatitis C patients: a prospective study. J Viral Hepat 2004; 11: 136\u2013140.","journal-title":"J Viral Hepat"},{"key":"BFgene201511_CR33","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1053\/j.gastro.2006.09.052","volume":"131","author":"T Marcello","year":"2006","unstructured":"Marcello T, Grakoui A, Barba-Spaeth G, Machlin ES, Kotenko SV, MacDonald MR et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006; 131: 1887\u20131898.","journal-title":"Gastroenterology"},{"key":"BFgene201511_CR34","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1084\/jem.20131557","volume":"211","author":"FH Duong","year":"2014","unstructured":"Duong FH, Trincucci G, Boldanova T, Calabrese D, Campana B, Krol I et al. IFN-lambda receptor 1 expression is induced in chronic hepatitis C and correlates with the IFN-lambda3 genotype and with nonresponsiveness to IFN-alpha therapies. J Exp Med 2014; 211: 857\u2013868.","journal-title":"J Exp Med"},{"key":"BFgene201511_CR35","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1002\/hep.21853","volume":"46","author":"JJ Feld","year":"2007","unstructured":"Feld JJ, Nanda S, Huang Y, Chen W, Cam M, Pusek SN et al. Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatology 2007; 46: 1548\u20131563.","journal-title":"Hepatology"},{"key":"BFgene201511_CR36","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1053\/j.gastro.2006.08.043","volume":"131","author":"G Randall","year":"2006","unstructured":"Randall G, Chen L, Panis M, Fischer AK, Lindenbach BD, Sun J et al. Silencing of USP18 potentiates the antiviral activity of interferon against hepatitis C virus infection. Gastroenterology 2006; 131: 1584\u20131591.","journal-title":"Gastroenterology"},{"key":"BFgene201511_CR37","doi-asserted-by":"publisher","first-page":"e84026","DOI":"10.1371\/journal.pone.0084026","volume":"8","author":"A Amanzada","year":"2013","unstructured":"Amanzada A, Kopp W, Spengler U, Ramadori G, Mihm S . Interferon-lambda4 (IFNL4) transcript expression in human liver tissue samples. PloS One 2013; 8: e84026.","journal-title":"PloS One"},{"key":"BFgene201511_CR38","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1002\/hep.27010","volume":"59","author":"S Petta","year":"2014","unstructured":"Petta S, Cabibbo G, Enea M, Macaluso FS, Plaia A, Bruno R et al. Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. Hepatology 2014; 59: 1692\u20131705.","journal-title":"Hepatology"},{"key":"BFgene201511_CR39","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nbt1385","volume":"26","author":"GK Geiss","year":"2008","unstructured":"Geiss GK, Bumgarner RE, Birditt B, Dahl T, Dowidar N, Dunaway DL et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol 2008; 26: 317\u2013325.","journal-title":"Nat Biotechnol"}],"container-title":["Genes &amp; Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/gene201511.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/gene201511","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/gene201511.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T18:35:05Z","timestamp":1647974105000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/gene201511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,28]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["BFgene201511"],"URL":"https:\/\/doi.org\/10.1038\/gene.2015.11","relation":{},"ISSN":["1466-4879","1476-5470"],"issn-type":[{"value":"1466-4879","type":"print"},{"value":"1476-5470","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,28]]},"assertion":[{"value":"1 November 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}